A detailed history of Alps Advisors Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Alps Advisors Inc holds 37,889 shares of PRTA stock, worth $764,600. This represents 0.01% of its overall portfolio holdings.

Number of Shares
37,889
Previous 36,530 3.72%
Holding current value
$764,600
Previous $1.33 Million 29.31%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$24.75 - $40.66 $33,635 - $55,256
1,359 Added 3.72%
37,889 $938,000
Q4 2023

Feb 14, 2024

SELL
$32.31 - $52.32 $96,736 - $156,646
-2,994 Reduced 7.58%
36,530 $1.33 Million
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $35,380 - $52,808
748 Added 1.93%
39,524 $1.91 Million
Q2 2023

Aug 14, 2023

BUY
$48.26 - $78.59 $199,892 - $325,519
4,142 Added 11.96%
38,776 $2.65 Million
Q1 2023

May 10, 2023

BUY
$46.97 - $58.27 $87,270 - $108,265
1,858 Added 5.67%
34,634 $1.68 Million
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $374,031 - $467,090
7,186 Added 28.08%
32,776 $1.97 Million
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $54,848 - $132,173
-2,180 Reduced 7.85%
25,590 $1.55 Million
Q2 2022

Aug 11, 2022

SELL
$22.73 - $39.98 $459,418 - $808,075
-20,212 Reduced 42.12%
27,770 $754,000
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $179,682 - $292,169
-5,936 Reduced 11.01%
47,982 $1.76 Million
Q4 2021

Feb 09, 2022

SELL
$42.11 - $73.26 $54,237 - $94,358
-1,288 Reduced 2.33%
53,918 $2.66 Million
Q3 2021

Nov 15, 2021

SELL
$48.2 - $78.89 $128,886 - $210,951
-2,674 Reduced 4.62%
55,206 $3.93 Million
Q2 2021

Aug 11, 2021

SELL
$21.63 - $57.65 $310,109 - $826,528
-14,337 Reduced 19.85%
57,880 $2.98 Million
Q1 2021

May 07, 2021

BUY
$11.0 - $28.24 $869 - $2,230
79 Added 0.11%
72,217 $1.81 Million
Q4 2020

Feb 03, 2021

BUY
$10.12 - $13.94 $730,036 - $1.01 Million
72,138 New
72,138 $866,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $947M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.